Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-60366 in EGFR-Mutant Non-Small Cell Lung Cancer
NCT06685718Phase 1Terminated
- Sponsor
- BeOne Medicines
- Start
- Dec 2024
- Primary completion
- Apr 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 7
01
Overview
Phase 1, open-label trial of BG-60366 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 24 months, Maximum Tolerated Dose or Maximum Administered Dose at 1 month and 2 more. Started Dec 2024; status: terminated.
02
Drugs
BG-60366
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06685718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685718.